Investor Relations

We are a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. We improve compliance, absorption, and more with our proprietary drug delivery technology.

Raymond James 42nd Annual Institutional Investors Conference
 Monday, March 1, 2021
 11:40am EST